| Rethinking screening for breast cancer and prostate cancer L Esserman, Y Shieh, I Thompson Jama 302 (15), 1685-1692, 2009 | 716 | 2009 |
| Breast cancer screening in the precision medicine era: risk-based screening in a population-based trial Y Shieh, M Eklund, L Madlensky, SD Sawyer, CK Thompson, ... Journal of the National Cancer Institute 109 (5), djw290, 2017 | 246 | 2017 |
| Breast cancer risk prediction using a clinical risk model and polygenic risk score Y Shieh, D Hu, L Ma, S Huntsman, CC Gard, JWT Leung, JA Tice, ... Breast cancer research and treatment 159, 513-525, 2016 | 170 | 2016 |
| Population-based screening for cancer: hope and hype Y Shieh, M Eklund, GF Sawaya, WC Black, BS Kramer, LJ Esserman Nature reviews Clinical oncology 13 (9), 550-565, 2016 | 146 | 2016 |
| Characterizing the impact of 25 years of DCIS treatment EM Ozanne, Y Shieh, J Barnes, C Bouzan, ES Hwang, LJ Esserman Breast cancer research and treatment 129, 165-173, 2011 | 134 | 2011 |
| Impact of mammographic screening on the detection of good and poor prognosis breast cancers LJ Esserman, Y Shieh, EJT Rutgers, M Knauer, VP Retèl, S Mook, ... Breast cancer research and treatment 130, 725-734, 2011 | 129 | 2011 |
| Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype Y Shieh, CG Scott, MR Jensen, AD Norman, KA Bertrand, VS Pankratz, ... Breast Cancer Research 21, 1-9, 2019 | 72 | 2019 |
| A polygenic risk score for breast cancer in US Latinas and Latin American women Y Shieh, L Fejerman, PC Lott, K Marker, SD Sawyer, D Hu, S Huntsman, ... JNCI: Journal of the National Cancer Institute 112 (6), 590-598, 2020 | 68 | 2020 |
| Low-dose CT scan for lung cancer screening: clinical and coding considerations Y Shieh, M Bohnenkamp Chest 152 (1), 204-209, 2017 | 55 | 2017 |
| A role for biomarkers in the screening and diagnosis of breast cancer in younger women LJ Esserman, Y Shieh, JW Park, EM Ozanne Expert review of molecular diagnostics 7 (5), 533-544, 2007 | 35 | 2007 |
| Joint relative risks for estrogen receptor-positive breast cancer from a clinical model, polygenic risk score, and sex hormones Y Shieh, D Hu, L Ma, S Huntsman, CC Gard, JWT Leung, JA Tice, E Ziv, ... Breast cancer research and treatment 166, 603-612, 2017 | 32 | 2017 |
| The WISDOM study: a new approach to screening can and should be tested L Esserman, M Eklund, L Veer, Y Shieh, J Tice, E Ziv, A Blanco, C Kaplan, ... Breast cancer research and treatment, 1-6, 2021 | 29 | 2021 |
| Medications for primary prevention of breast cancer Y Shieh, JA Tice Jama 324 (3), 291-292, 2020 | 23 | 2020 |
| A response to “Personalised medicine and population health: breast and ovarian cancer” A Antoniou, H Anton-Culver, A Borowsky, M Broeders, J Brooks, ... Human genetics 138, 287-289, 2019 | 17 | 2019 |
| Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial H Keane, YS Huilgol, Y Shieh, JA Tice, J Belkora, K Sepucha, WP Shibley, ... NPJ Breast Cancer 7 (1), 78, 2021 | 16 | 2021 |
| Development and testing of a polygenic risk score for breast cancer aggressiveness Y Shieh, J Roger, C Yau, DM Wolf, GL Hirst, LB Swigart, S Huntsman, ... NPJ precision oncology 7 (1), 42, 2023 | 6 | 2023 |
| Interval breast cancers—insights into a complex phenotype Y Shieh, E Ziv, K Kerlikowske Nature Reviews Clinical Oncology 17 (3), 138-139, 2020 | 4 | 2020 |
| Abstract P5-08-01: Breast cancer risk thresholds as a predictor of chemoprevention uptake in the Athena Breast Health Network YS Huilgol, H Keane, Y Shieh, J Tice, E Ziv, L Madlensky, L Sabacan, ... Cancer Research 80 (4_Supplement), P5-08-01-P5-08-01, 2020 | 4 | 2020 |
| Detection of ductal carcinoma in situ and subsequent interval cancers Y Shieh, M Eklund, L Esserman BMJ 352, 2016 | 4 | 2016 |
| Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry YS Huilgol, H Keane, Y Shieh, RA Hiatt, JA Tice, L Madlensky, L Sabacan, ... NPJ breast cancer 7 (1), 102, 2021 | 3 | 2021 |
